Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2020

Disaggregation of Revenue [Abstract]

Disaggregation of Revenue [Table Text Block]

The following table summarizes the disaggregation of revenue by nature:

	Three Months Ended March 31,
Dollars in Millions	2020		2019
Net product sales	$	10,541	$	5,713
Alliance revenues	105		129
Other revenues	135		78
Total Revenues	$	10,781	$	5,920

Revenue Recognition, Discounts [Policy Text Block]

The following table summarizes GTN adjustments:

	Three Months Ended March 31,
Dollars in Millions	2020			2019
Gross product sales	$	14,686		$	7,994
GTN adjustments(a)
Charge-backs and cash discounts	(1,340		)	(774		)
Medicaid and Medicare rebates	(1,498		)	(800		)
Other rebates, returns, discounts and adjustments	(1,307		)	(707		)
Total GTN adjustments	(4,145		)	(2,281		)
Net product sales	$	10,541		$	5,713

(a)

Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $72 million and $78 million for the three months ended March 31, 2020 and 2019, respectively.

Revenue from External Customers by Products and Services [Table Text Block]

The following table summarizes the disaggregation of revenue by product and region:

	Three Months Ended March 31,
Dollars in Millions	2020		2019
Prioritized Brands
Revlimid	$	2,915	$	—
Eliquis	2,641		1,925
Opdivo	1,766		1,801
Orencia	714		640
Pomalyst/Imnovid	713		—
Sprycel	521		459
Yervoy	396		384
Abraxane	300		—
Empliciti	97		83
Reblozyl	8		—
Inrebic	12		—
Established Brands
Baraclude	122		141
Vidaza	158		—
Other Brands(a)	418		487
Total Revenues	$	10,781	$	5,920
United States	$	6,766	$	3,449
Europe	2,567		1,480
Rest of the World	1,335		874
Other(b)	113		117
Total Revenues	$	10,781	$	5,920

(a) Includes BMS and Celgene products in 2020.

(b)

Other revenues include royalties and alliance-related revenues for products not sold by BMS's regional commercial organizations.